For the quarter ending 2025-09-30, INBX has $177,471K in assets. $140,641K in debts. $153,088K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 153,088 | 186,567 | ||
| Accounts receivable-Nonrelated Party | 110 | 237 | ||
| Other receivables | 727 | 730 | ||
| Accounts receivable-Related Party | 0 | 0 | ||
| Prepaid expenses and other current assets | 7,498 | 6,430 | ||
| Total current assets | 161,423 | 193,964 | ||
| Property and equipment, net | 4,306 | 4,885 | ||
| Operating right-of-use asset | 6,004 | 6,460 | ||
| Other non-current assets | 5,738 | 6,809 | ||
| Total assets | 177,471 | 212,118 | ||
| Accounts payable | 6,773 | 8,292 | ||
| Accrued expenses | 26,963 | 28,478 | ||
| Current portion of operating lease liability | 2,247 | 2,169 | ||
| Total current liabilities | 35,983 | 38,939 | ||
| Long-term debt, net | 99,917 | 99,279 | ||
| Non-current portion of operating lease liability | 4,741 | 5,341 | ||
| Total liabilities | 140,641 | 143,559 | ||
| Common stock, 0.0001 par value 120,000,000 shares authorized as of september30, 2025 and december31, 2024 14,498,093 and 14,475,904 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 1 | 1 | ||
| Additional paid-in-capital | 250,182 | 246,655 | ||
| Accumulated deficit | -213,353 | -178,097 | ||
| Total stockholders equity | 36,830 | 68,559 | ||
| Total liabilities and stockholders equity | 177,471 | 212,118 | ||
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)